WALTHAM, Mass., Sept. 25, 2019 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO) ("Thermo
Fisher") announced today that it has priced an offering of
€4.4 billion aggregate principal amount (the "Euro Offering") of
euro-denominated notes (collectively, the "Euro Notes") and an
offering of $900 million aggregate
principal amount (the "USD Offering" and, together with the Euro
Offering, the "Offerings") of USD-denominated notes (collectively,
the "USD Notes"). The following notes were priced:
- €800 million aggregate principal amount of its 0.125% senior
notes due 2025, at the issue price of 99.114% of their principal
amount,
- €800 million aggregate principal amount of its 0.500% senior
notes due 2028, at the issue price of 99.060% of their principal
amount,
- €900 million aggregate principal amount of its 0.875% senior
notes due 2031, at the issue price of 99.243% of their principal
amount,
- €900 million aggregate principal amount of its 1.500% senior
notes due 2039, at the issue price of 99.743% of their principal
amount,
- €1,000 million aggregate principal amount of its 1.875% senior
notes due 2049, at the issue price of 98.465% of their principal
amount, and
- $900 million aggregate principal
amount of its 2.600% senior notes due 2029, at the issue price of
99.861% of their principal amount.
The Euro Offering is expected to close on or about September 30, 2019, and the USD Offering is
expected to close on or about October 8,
2019, subject to customary closing conditions. The Euro
Notes will pay interest on an annual basis. The USD Notes will pay
interest on a semi-annual basis. Closing of the Euro Offering is
not contingent upon the completion of the USD Offering, and closing
of the USD Offering is not contingent upon the completion of the
Euro Offering.
Thermo Fisher intends to use the
net proceeds of the Offerings (together with cash on hand) to repay
commercial paper issued to fund the redemption on September 27, 2019, of $300 million aggregate principal amount of its
4.70% Senior Notes due 2020 and $800
million aggregate principal amount of its 3.15% Senior Notes
due 2023, and to fund the redemption of approximately $4.5 billion aggregate principal amount of
outstanding senior notes issued by Thermo
Fisher or its subsidiaries, including all of the outstanding
6.00% Senior Notes due 2020 and 5.00% Senior Notes due 2021 issued
by its subsidiary Life Technologies Corporation, of which notice is
expected to be provided to holders tomorrow.
The joint book-running managers for the Euro Offering are
Goldman Sachs & Co. LLC, Merrill Lynch International, Citigroup
Global Markets Limited and J.P. Morgan Securities plc. The joint
book-running managers for the USD Offering are Goldman Sachs &
Co. LLC, BofA Securities, Inc., Credit Suisse Securities
(USA) LLC and HSBC Securities (USA) Inc.
The Offerings are being made pursuant to an effective
registration statement on Form S-3 filed with the U.S. Securities
and Exchange Commission (the "SEC"). Prospective investors should
read the prospectus forming a part of that registration statement
and the separate prospectus supplements related to the Offerings
and the other documents that Thermo
Fisher has filed with the SEC for more complete information
about Thermo Fisher and the
Offerings. These documents are available at no charge by visiting
EDGAR on the SEC website at www.sec.gov. Alternatively,
Thermo Fisher, the underwriters or
any dealer participating in the Euro Offering will arrange to send
you the related prospectus if you request it by calling Merrill
Lynch International toll-free at 1-800-294-1322; Goldman Sachs
& Co. LLC toll-free at 1-866-471-2526; Citigroup Global Markets
Limited toll-free at 1-800-831-9146; or J.P. Morgan Securities plc
collect on +44-207-134-2468; and Thermo
Fisher, the underwriters or any dealer participating in the
USD Offering will arrange to send you the related prospectus if you
request it by calling BofA Securities, Inc. toll-free at
1-800-294-1322; Goldman Sachs & Co. LLC toll-free at
1-866-471-2526; Credit Suisse Securities (USA) LLC at 1-800-221-1037; or HSBC Securities (USA) Inc. toll-free at 1-866-811-8049.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about Thermo Fisher's intended use of proceeds.
These statements involve a number of risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including risks and uncertainties relating to
capital markets conditions and completion of the Offerings.
Additional important factors and information regarding Thermo Fisher's business that could cause actual
results to differ materially from those indicated by such
forward-looking statements are set forth in the prospectus and
prospectus supplements dated September 24,
2019 related to the Offerings, which are on file with the
SEC and available in the "Investors" section of our website under
the heading "SEC Filings," and the documents incorporated by
reference into the prospectus and prospectus supplement for each of
the Offerings. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so, even if circumstances change and,
therefore, you should not rely on these forward-looking statements
as representing our views as of any date subsequent to today.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original
content:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-prices-offering-of-senior-notes-300925086.html
SOURCE Thermo Fisher Scientific